Pfizer Inc.
NYSE:PFEDrug Manufacturers - General
-$0.71 today
- Market cap
- $159.94B
- Beta
- 0.29
- P/E (TTM)
- 19.2
- EPS (TTM)
- $1.32
- Dividend yield
- 6.82%
Volume 37.37M
Average 36.66M
PFE Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Pfizer Inc.NYSE: PFE
Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026
Stock-based compensation growth accelerates
Q2 FY2026 stock-based compensation of $249M rose 22.7% year over year, ahead of the +14.9% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 8.5% from the prior quarter. Over 3 fiscal years it compounded at -2.9% a year.
Context
- Stock-based compensation amounted to 1.3% of revenue in FY2025, down 0.1 pp from a year earlier.
- Stock-based compensation increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +22.7% holds above the trailing-twelve-month pace of +14.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 799M USD
- Year-over-year change
- -8.9%
- 4-year CAGR
- -9.3%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 799M | -8.9% |
| FY2024 | 2024-12-31 | 877M | +67.0% |
| FY2023 | 2023-12-31 | 525M | -39.8% |
| FY2022 | 2022-12-31 | 872M | -26.2% |
| FY2021 | 2021-12-31 | 1.18B | — |
Stock-Based Compensation vs competitors
How PFE compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +14.9% is the highest of 9, against a peer median of +5.1%.
- Stock-based compensation amounts to 1.5% of revenue for PFE, versus a peer median of 1.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $1.42B USD | +11.0% | +6.0% | 1.4% | |
| LTM Jun 2026 | $976M USD | +4.5% | +12.5% | 1.5% | |
| LTM Jun 2026 | $947M USD | +14.9% | -2.9% | 1.5% | |
| LTM Jun 2026 | $892M USD | +12.5% | — | 1.3% | |
| LTM Jun 2026 | $649.2M USD | +5.8% | +19.0% | 0.8% | |
| LTM Jun 2026 | $571M USD | -45.9% | — | 1.0% | |
| LTM Jun 2026 | $553M USD | +4.3% | +6.6% | 1.1% | |
| LTM Jun 2026 | $460M USD | -47.2% | +11.6% | 1.5% | |
| LTM Jun 2026 | €184M EUR | +7.6% | — | 0.4% | |
| LTM Sep 2026 | $0 USD | — | — | 0.0% | |
| LTM Jun 2026 | £0 GBP | — | — | 0.0% | |
| Peer median (excluding PFE) | — | +5.1% | +11.6% | 1.1% | |
Competitors are the stored peer set for PFE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 22.46B | 31.4B | 2.17B | 8.05B | 7.79B |
| Depreciation & Amortization | 5.19B | 5.06B | 6.29B | 7.01B | 6.59B |
| Deferred Income Tax | (4.29B) | (3.76B) | (3.44B) | (2.1B) | (2.13B) |
| Stock-Based Compensation | 1.18B | 872M | 525M | 877M | 799M |
| Change in Working Capital | 12.8B | (4.46B) | (2.17B) | (3.07B) | (5.35B) |
| Accounts Receivables | (3.81B) | 261M | 347M | (109M) | (263M) |
| Inventory | (1.13B) | 592M | (1.17B) | (854M) | 561M |
| Accounts Payables | 1.24B | 1.19B | (300M) | (1.02B) | (469M) |
| Other Working Capital | 16.5B | (6.5B) | (1.05B) | (1.08B) | (5.18B) |
| Other Non-Cash Items | (4.76B) | 150M | 5.33B | 1.97B | 4.01B |
| Operating Cash Flow | 32.58B | 29.27B | 8.7B | 12.74B | 11.71B |
| Capital Expenditures | (2.71B) | (3.24B) | (3.91B) | (2.91B) | (2.63B) |
| Acquisitions (Net) | (12M) | (23B) | (43.43B) | 7.04B | (6.93B) |
| Purchases of Investments | (47.61B) | (38.78B) | (31.18B) | (10.31B) | (14.65B) |
| Sales of Investments | 28.1B | 45.46B | 46.42B | 8.83B | 22.69B |
| Other Investing Activities | (306M) | 3.77B | (180M) | 0 | 165M |
| Investing Cash Flow | (22.55B) | (15.78B) | (32.28B) | 2.65B | (1.35B) |
| Debt Repayment | (1.1B) | (3.52B) | 35.95B | (7.16B) | (74M) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 0 |
| Common Stock Repurchased | 0 | (2B) | 0 | 0 | 0 |
| Dividends Paid | (8.73B) | (8.98B) | (9.25B) | (9.51B) | (9.77B) |
| Other Financing Activities | 16M | (335M) | (632M) | (469M) | (459M) |
| Financing Cash Flow | (9.82B) | (14.83B) | 26.07B | (17.14B) | (10.3B) |
| Effect of Forex Changes | (60M) | (165M) | (40M) | (66M) | 49M |
| Net Change in Cash | 158M | (1.52B) | 2.45B | (1.81B) | 99M |
| Free Cash Flow | 29.87B | 26.03B | 4.79B | 9.84B | 9.08B |
Pfizer Inc.
NYSE:PFE
Intrinsic Alpha fair value
Locked
Current Price
$28.06
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.